Perseus Proteomics (TYO:4882) presented phase I results of its anti-TfR1 antibody, PPMX-T003, at the 66th ASH Annual Meeting, according to a Tuesday filing on the Tokyo Stock Exchange.
The trial, conducted with six polycythemia vera patients, showed no serious adverse effects and demonstrated efficacy, with five patients completing 12 weeks without phlebotomy, the filing said.
The company is also developing other antibody therapies for cancer.
Price (JPY): $742.00, Change: $+22, Percent Change: +3.06%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.